Top of the page.
Skip the menu to main contents.
Move to main menu.
Skip to main contents.


What's New

The information in news releases is current at the time of the release. Note that the information shown here may not be latest information and may be subject to change without prior notice.

What's New

Feb. 15, 2021
Fujifilm Kyowa Kirin Biologics and Mylan EPD Announce Launch of Biosimilar Adalimumab in Japan (PDF: 512KB)
Sep. 29, 2020
Centus Biotherapeutics Receives European Marketing Authorization for Equidacent®, Biosimilar Avastin® (PDF: 76KB)
Jul. 27, 2020
Centus Biotherapeutics Announces Positive CHMP Opinion for FKB238, Biosimilar Bevacizumab (PDF: 492KB)
Jul. 9, 2020
Mylan and Fujifilm Kyowa Kirin Biologics Announce U.S. FDA Approval of Hulio® (adalimumab-fkjp) (PDF: 490KB)
Jun. 29, 2020
Fujifilm Kyowa Kirin Biologics Announces Approval of “Adalimumab (Genetical Recombination) [Adalimumab Biosimilar 1]” in Japan (PDF: 409KB)
Sep. 20, 2018
Mylan and FKB Receive European Marketing Authorization for Hulio®, Biosimilar Adalimumab (PDF: 554KB)
Jul. 27, 2018
Mylan and FKB announce Positive CHMP Opinion for Hulio, Biosimilar Adalimumab (PDF: 187KB)
Apr. 11, 2018
Fujifilm Kyowa Kirin Biologics Partners with Mylan to Commercialize Biosimilar to Humira® (adalimumab) (PDF: 57KB)
Nov. 8, 2017
Fujifilm Kyowa Kirin Biologics co. Ltd., presented results from Phase 3 studies consisted of Randomized Double-Blind and Open-Label Extension Studies in Patients with Rheumatoid Arthritis, Demonstrating clinical similarity of FKB327 with Adalimumab including switching treatment at 2017 ACR (PDF: 209KB)
Oct. 1, 2017
Fujifilm Kyowa Kirin Biologics Co., Ltd. (FKB) today announced that its Board of Directors has appointed Yoshifumi Torii, Ph.D. as Chief Executive Officer (CEO). (PDF: 59KB)
Jun. 22, 2017
Fujifilm Kyowa Kirin Biologics Presents Results from Randomized Phase 3 Study in Patient with Rheumatoid Arthritis, Demonstrating Clinical Equivalence of FKB327 with Adalimumab at 2017 EULAR (PDF: 142KB)
May. 22, 2017
Announces Marketing Authorisation Application for FKB327 Accepted for Review by European Medicines Agency (PDF: 57KB)
Apr. 28, 2017
The homepage was renewed.
Mar. 3, 2017
The UK High Court of Justice (Patents) Rules in Fujifilm Kyowa Kirin Biologics' Favor on Rheumatoid Arthritis, Psoriasis and Psoriatic Arthritis Dosing Regimens for Adalimumab are Obvious and Unpatentable
Text Size

Back number

Back to Top